#ObesityDrug

Yonhap Infomax Newsinfomaxkorea
2025-10-28

Hanmi Pharmaceutical shares surged 26% after positive Phase 3 obesity drug results, boosting R&D optimism, though analysts warn of overheating amid upcoming clinical milestones.

en.infomaxai.com/news/articleV

Yonhap Infomax Newsinfomaxkorea
2025-10-23

Citi Group has upgraded BioAge Labs to 'Buy' and doubled its price target, citing strong prospects for its obesity drug pipeline and upcoming data releases.

en.infomaxai.com/news/articleV

Yonhap Infomax Newsinfomaxkorea
2025-08-20

Viking Therapeutics shares plunged 42% after interim Phase 2 trial data for its oral obesity drug VK2735 revealed high dropout rates and side effects, disappointing investors despite comparable weight loss efficacy to competitors.

en.infomaxai.com/news/articleV

Yonhap Infomax Newsinfomaxkorea
2025-06-23

Novo Nordisk shares tumbled over 5% after new obesity drug data disappointed investors, intensifying concerns that Eli Lilly could dominate the fast-growing weight-loss treatment market.

en.infomaxai.com/news/articleV

Yonhap Infomax Newsinfomaxkorea
2025-03-10

US biotech firm Terns Pharmaceuticals sees potential 5-fold stock increase on promising obesity drug developments and analyst optimism

en.infomaxai.com/news/articleV

2024-09-19

In an election year when both presidential candidates are tapping into anger about #DrugPrices, both #ObesityDrug makers and #PBMs are feeling INTENSE heat.
conscienhealth.org/2024/09/obe

Client Info

Server: https://mastodon.social
Version: 2025.07
Repository: https://github.com/cyevgeniy/lmst